Clinical

Dataset Information

0

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors


ABSTRACT: This research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (MEK) Inhibitor) and SAR245409 (Phosphatidylinositol 3-kinase (Pi3K)/Mammalian Target of Rapamycin (mTOR) inhibitor), in the treatment of locally advanced or metastatic solid tumors. The primary purpose of the study is to determine the maximum tolerated dose of the drug combination.

DISEASE(S): Solid Tumor,Metastatic Solid Tumor,Melanoma,Colorectal Cancer,Non Small Cell Lung Cancer,Breast Cancer,Neoplasms,Locally Advanced Solid Tumor

PROVIDER: 2109499 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2013-12-14 | E-GEOD-53309 | biostudies-arrayexpress
2013-12-14 | GSE53309 | GEO
2017-05-30 | GSE82032 | GEO
2015-08-13 | E-GEOD-71981 | biostudies-arrayexpress
2017-01-18 | GSE93695 | GEO
2015-10-05 | GSE48643 | GEO
2018-04-05 | GSE111005 | GEO
2020-05-26 | PXD013988 | Pride
2015-08-13 | GSE71981 | GEO
2019-04-27 | GSE130396 | GEO